Safety outcome
epigastralgia, asthenia, nausea, tachycardia, dyspepsia, vaginitis, COVID-19 disease, polytraumatism, urticaria, dizziness, skin rash, pruritus, nausea,, presyncope
VAGINITIS, ADVERSE EVENTS, HERPES INFECTION, CHOLELITHIASIS, URTICARIA, PARAESTHESIA
Twenty-three patients (13.3%) experienced adverse events, 14 patients in the domperidone group (16.1%) and 9 patients in the placebo group (10.5%), with no statistically significant difference (Six adverse events were considered possibly related to domperidone (digestive discomfort, dizziness, dyspepsia, epigastralgia, tongue pruritus and tachycardia) and nine unknowns (asthenia, cholelithiasis, increased blood pressure, herpes infection, urticaria, oxygen saturation decrease, nausea, palpitations, paraesthesia, polytraumatism, presyncope, skin rash and vaginitis), with 13 adverse events not related to the study treatment.Eight adverse events in the placebo group (dizziness, tongue pruritus, nausea, asthenia, paraesthesia, presyncope, epigastralgia, tachycardia) and two adverse events in the domperidone group (abdominal discomfort and dyspepsia) lead to discontinuation of the study drug (No patients needed to be hospitalized due to the COVID-19 disease, neither needing oxygen therapy. None of the patients died at 28 days after completion of the study.